PolyPeptide Group

PolyPeptide Group is a prominent Contract Development and Manufacturing Organization (CDMO) serving the global pharmaceutical and biotechnology sectors. Founded in 1952, the company has established itself as a leader in the production of proprietary and generic GMP-grade peptides. With a focus on high-quality molecular synthesis, the firm supports clients through every stage of development, from initial research to large-scale commercial production.

The organization operates with a robust workforce of 1,000-5,000 employees across 8 global locations. Their technical expertise spans liquid and solid-phase peptide synthesis, hybrid protocols, and the production of stable isotope-labeled molecules. Meet PolyPeptide Group's team to understand the specialized engineering and scientific talent driving their manufacturing processes. Their infrastructure is designed to handle complex pharmaceutical requirements, ensuring compliance with rigorous international quality standards for both custom research and large-scale manufacturing projects.

As a specialized CDMO, PolyPeptide Group maintains a competitive edge by integrating advanced biotechnology with scalable production capabilities. The company’s core expertise in peptide chemistry allows it to address the evolving needs of the healthcare industry, providing essential components for drug development and therapeutic applications. By maintaining a focus on long-term partnerships and technical innovation, the firm continues to expand its influence within the pharmaceutical supply chain, delivering reliable, high-grade solutions for complex molecular challenges in a highly regulated global market.